Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
Blazevic A, Edwards RL, Xia M, Eickhoff CS, Hamzabegovic F, Meza KA, Ning H, Tennant J, Mosby KJ, Ritchie JC, Girmay T, Lai L, McCullough M, Beck A, Kelley C, Edupuganti S, Kabbani S, Buchanan W, Makhene MK, Voronca D, Cherikh S, Goll JB, Rouphael NG, Mulligan MJ, Hoft DF. Blazevic A, et al. Among authors: goll jb. J Infect Dis. 2024 May 15;229(5):1498-1508. doi: 10.1093/infdis/jiad441. J Infect Dis. 2024. PMID: 38019956 Clinical Trial.
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg J, Zhang L, Gore S, Al Baghdadi T, Maciejewski J, Liu J, Padron E, Komrojki R, Saber W, Abel G, Kroft SH, Harrington A, Grimes T, Reed H, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. DeZern AE, et al. Among authors: goll jb. Blood Adv. 2023 Jul 25;7(14):3749-3759. doi: 10.1182/bloodadvances.2022008578. Blood Adv. 2023. PMID: 36947201 Free PMC article.
Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies.
Goll JB, Bosinger SE, Jensen TL, Walum H, Grimes T, Tharp GK, Natrajan MS, Blazevic A, Head RD, Gelber CE, Steenbergen KJ, Patel NB, Sanz P, Rouphael NG, Anderson EJ, Mulligan MJ, Hoft DF. Goll JB, et al. Front Immunol. 2023 Feb 23;14:1163550. doi: 10.3389/fimmu.2023.1163550. eCollection 2023. Front Immunol. 2023. PMID: 36911714 Free PMC article.
The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies.
Goll JB, Bosinger SE, Jensen TL, Walum H, Grimes T, Tharp GK, Natrajan MS, Blazevic A, Head RD, Gelber CE, Steenbergen KJ, Patel NB, Sanz P, Rouphael NG, Anderson EJ, Mulligan MJ, Hoft DF. Goll JB, et al. Front Immunol. 2023 Jan 19;13:1093242. doi: 10.3389/fimmu.2022.1093242. eCollection 2022. Front Immunol. 2023. PMID: 36741404 Free PMC article. Clinical Trial.
The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination.
Goll JB, Jain A, Jensen TL, Assis R, Nakajima R, Jasinskas A, Coughlan L, Cherikh SR, Gelber CE, Khan S, Huw Davies D, Meade P, Stadlbauer D, Strohmeier S, Krammer F, Chen WH, Felgner PL. Goll JB, et al. NPJ Vaccines. 2022 Aug 30;7(1):103. doi: 10.1038/s41541-022-00524-7. NPJ Vaccines. 2022. PMID: 36042229 Free PMC article.
34 results